Back

Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

27 August 2021 (20:33 - 20:42)
Organised by:
Congress Presentation Part of: Can we improve outcomes by targeting metabolic risk? Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Wen Sun

The Chinese University of Hong Kong, Shatin (Hong Kong)

4 More presentations in this session

Presentation thumbnail
Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Doctor M. Segar (Houston, US)
Abstract Slides Video
Presentation thumbnail
Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial
Doctor P. Myhre (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial
Doctor F. Cosentino (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Can we improve outcomes by targeting metabolic risk?

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 20:33 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources